Skip to main content

Overview

Dr Gauthier’s particular clinical research interests are in clinical trial design and the longitudinal study of clinical progression of MS. Specifically, she is interested in the application of improved statistical methods to predict disease progression and response to treatment. She has also been actively involved in numerous clinical trials, including phase I, II, and III trials, using novel therapies for the treatment of MS.

Highlights

  1. 1
    Scientific reports · 2022
    PMID: 35292734PMCID: PMC8924224DOISenior author51 citations
  2. 2
    Neurology(R) neuroimmunology & neuroinflammation · 2022
    PMID: 35046083PMCID: PMC8771666DOISenior author47 citations
  3. 3
    NeuroImage · 2020
    PMID: 33069865PMCID: PMC7805079DOISenior author12 citations

Publications

109 publications

Active

9 grants
  • MPI
    Multi-scale, multi-modal imaging assessment of trajectories of cognitive impairment in Multiple Sclerosis
    National Institute of Neurological Disorders and Stroke · 2024–2029
  • MPI
    Quantification of the innate immune activity within chronic lesions as a novel treatment biomarker in Multiple Sclerosis
    National Institute of Neurological Disorders and Stroke · 2024–2029
  • Co-I
    Immune Privilege, CNS Autoimmunity, and Clostridium perfringens Epsilon Toxin
    National Institute of Allergy and Infectious Diseases · 2023–2028
  • Sub-PI
    Variability Measures in the Assessment of Paramagnet
    National Multiple Sclerosis Society · 2025–2028 · via Vanderbilt University Medical Center
    RG-2407-43760
  • Co-I
    Harboring the Initial Trigger of Multiple Sclerosis
    National Multiple Sclerosis Society · 2023–2026
    RG-2512-45549
  • PI
    Establishing the clinical relevance of chronic active MS lesions and quantification of their inflammatory trajectory for a new treatment target
    National Multiple Sclerosis Society · 2022–2026
    NMSS 223937-03
  • KP
    New PET/CT System for Human and Non-human Primate Imaging
    Office of the Director, NIH · 2023–2026
  • Co-I
    Quantitative MRI of Lesion Iron and Myelin Repair
    National Multiple Sclerosis Society · 2016–2025
    RR-1602-07671
  • Co-I
    Multi-modal neuroimaging and cognitive assessment of females with multiple sclerosis across different stages of menopause
    National Multiple Sclerosis Society · 2023–2025
    NMSS TA-2204-39428
Completed grants (11)
  • KP
    7T Magnetic Resonance Imaging System for Basic, Translational and Clinical Research
    Office of the Director, NIH · 2021–2025
  • Sub-PI
    Race to Erase MS Innovation Award
    Race to Erase MS · 2021–2024 · via University of California, San Francisco
    A138740
  • PI
    Identifying mechanisms of tissue injury in MS lesions: a multi-modality imaging approach
    National Institute of Neurological Disorders and Stroke · 2018–2024
  • MPI
    No-Gd MRI for Monitoring Disease Status in Multiple Sclerosis
    National Institute of Neurological Disorders and Stroke · 2018–2024
  • PI
    Examination of extracellular vesicles in patients with chronic active MS lesions
    Myelin Repair Foundation · 2019–2023Contract
    SRA 202213-01
  • KP
    Major Cyclotron Upgrades and Refurbishment
    Office of the Director, NIH · 2021–2023
  • MPI
    Clinical Research Sites for the Network of Excellence in Neuroscience Clinical Trials (NeuroNEXT sites)
    National Institute of Neurological Disorders and Stroke · 2018–2023 · via Columbia University
  • Co-I
    Detection, Characterization and Treatment of Chronic Microglial Inflammation in Established MS Lesions
    National Institute of Neurological Disorders and Stroke · 2017–2022 · via Yale University
  • Co-I
    Multiple Sclerosis Lesion Magnetic Susceptibility Activity
    National Institute of Neurological Disorders and Stroke · 2015–2022
  • Co-I
    Quantifying the Role of the Connectome in Resiliency to Multiple Sclerosis
    National Institute of Neurological Disorders and Stroke · 2017–2021
  • KP
    NeuroNEXT
    National Institute of Neurological Disorders and Stroke · 2013–2018 · via Harvard Medical School

Clinical research

7 studies

Active

4 studies
  • PI
    Quantification of the innate immune activity within chronic lesions as a novel treatment biomarker in Multiple Sclerosis: a PET validation study
    Weill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2026)
  • PI
    Weill Cornell CNS Demyelinating Disorders Database
    Weill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2025)
  • PI
    Multi-scale, multi-modal imaging assessment of trajectories of cognitive impairment in Multiple Sclerosis
    Weill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2024)
  • PI
    Quantification of the innate immune activity within chronic lesions as a novel treatment biomarker in Multiple Sclerosis
    Weill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2024)
Completed & closed trials (3)
  • PI
    A Phase 2a Randomized, Double-Blind, Placebo-Controlled, Multicenter Dose-Ranging Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients
    PHASE2 · Tiziana Therapeutics INC · CLOSED TO ACCRUAL (as of 2026)
    Secondary Progressive Multiple Sclerosis
    NCT06292923
  • PI
    Evaluating the impact of Ocrelizumab on chronic active MS lesions utilizing quantitative susceptibility mapping and myelin water imaging - BRANYplus Transfer
    Weill Medical College of Cornell University · CLOSED TO ACCRUAL (as of 2025)
  • PI
    Evaluation of CNS Derived Extracellular Vesicles in MS Patients with Chronic Active Lesions
    Weill Medical College of Cornell University · CLOSED TO ACCRUAL (as of 2021)

External relationships

Advisory/Scientific Board Member

Novartis Pharmaceuticals Corporation

Other

Novartis Pharmaceuticals Corporation · Regeneron Pharmaceuticals, Inc.